PremiumThe FlyOvid Therapeutics price target lowered to $3 from $4 at Wedbush Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies Ovid Therapeutics sees cash runway into 2H26 PremiumThe FlyOvid Therapeutics upgraded to Outperform from Perform at Oppenheimer Ovid to present posters on pipeline program for neuronal hyperexcitability Ovid Therapeutics reports Q3 EPS (20c), consensus (20c) PremiumThe FlyOvid Therapeutics reduces headcount by 43% Ovid Therapeutics reports cash position of $77M as of June 30 Ovid Therapeutics reports Q2 EPS 12c, consensus (22c) 
